First Allied Advisory Services’s Arbutus Biopharma ABUS Stock Holding History

First Allied Advisory Services’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-11,200	Closed	-$236K	–	1029
2014 Q3	$236K	Buy	+11,200	New	+$183K	0.02%	840

Other funds holding ABUS

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

OSAM

O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

SIA

Sit Investment Associates Minneapolis, Minnesota $5.28B AUM 14.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

First Allied Advisory Services's ABUS Position: Q4 2014 in Review

First Allied Advisory Services sold out of Arbutus Biopharma (ABUS) in Q4 2014, closing a stake of 11,200 shares — an estimated $236K sold.

First Allied Advisory Services first reported a position in ABUS in Q3 2014 and held it in 1 quarter. The position peaked at $236K in Q3 2014. 49 funds tracked by Wall St. Rank hold ABUS as of Q4 2014.

First Allied Advisory Services reported no remaining Arbutus Biopharma position as of Q4 2014 after selling out during the quarter.
First Allied Advisory Services sold 11,200 Arbutus Biopharma shares in Q4 2014, an estimated $236K.
First Allied Advisory Services first reported a position in Arbutus Biopharma in Q3 2014 and held it in 1 quarter.
First Allied Advisory Services's Arbutus Biopharma position peaked at $236K in Q3 2014.
49 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2014.

Based on First Allied Advisory Services's 13F filing for Q4 2014, filed 9 Feb 2015.